Trial
NCT06248086
A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Astellas Pharma Global Development, Inc.
Collaborators
—
Condition
B-cell Lymphoma
Intervention
ASP2802
Why stopped
The termination of the study was a business decision made by the sponsor.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-28